BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Livideanu C, Lipsker D, Paul C, Juillard J, Schubert B. Pyoderma gangrenosum as initial manifestation of Graves' disease. Clin Exp Dermatol 2006;31:659-61. [DOI: 10.1111/j.1365-2230.2006.02184.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
Number Citing Articles
1 Dini V, Romanelli M, Bertone M, Talarico S, Bombardieri S, Barachini P. Improvement of Idiopathic Pyoderma Gangrenosum During Treatment With Anti-Tumor Necrosis Factor Alfa Monoclonal Antibody. The International Journal of Lower Extremity Wounds 2007;6:108-13. [DOI: 10.1177/1534734607300912] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
2 Coster A, Dargent J, de Visscher N, Levecque P, Roquet-gravy P. Pyoderma gangrenosum avec anticorps anti-cytoplasme des neutrophiles de type anti-protéinase 3 (PR3-ANCA) induits par le propylthiouracile. Annales de Dermatologie et de Vénéréologie 2017;144:368-73. [DOI: 10.1016/j.annder.2017.01.018] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Bonamigo RR, Razera F, Olm GS. Dermatoses neutrofílicas: parte I. An Bras Dermatol 2011;86:11-27. [DOI: 10.1590/s0365-05962011000100002] [Cited by in Crossref: 23] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
4 Ahronowitz I, Harp J, Shinkai K. Etiology and management of pyoderma gangrenosum: a comprehensive review. Am J Clin Dermatol. 2012;13:191-211. [PMID: 22356259 DOI: 10.2165/11595240-000000000-00000] [Cited by in Crossref: 209] [Cited by in F6Publishing: 159] [Article Influence: 23.2] [Reference Citation Analysis]
5 Weedon D. The vasculopathic reaction pattern. Weedon's Skin Pathology. Elsevier; 2010. pp. 195-244.e49. [DOI: 10.1016/b978-0-7020-3485-5.00009-7] [Cited by in Crossref: 11] [Article Influence: 1.0] [Reference Citation Analysis]
6 Schadt CR, Callen JP. Management of neutrophilic dermatoses. Dermatol Ther 2012;25:158-72. [PMID: 22741935 DOI: 10.1111/j.1529-8019.2012.01488.x] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
7 Wollina U, Tchernev G. Pyoderma gangrenosum: pathogenetic oriented treatment approaches. Wien Med Wochenschr 2014;164:263-73. [DOI: 10.1007/s10354-014-0285-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
8 Baldea A, Gamelli RL. Postoperative Pyoderma Gangrenosum After Elective Abdominoplasty: A Case Report and Review of the Literature: . Journal of Burn Care & Research 2010;31:959-63. [DOI: 10.1097/bcr.0b013e3181f93ab1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
9 Lamet S, Bracke A, Geluykens E, Vlieghe E, Seymons K, Gadisseur A, Vrelust I, Van Marck V, Somville J, Lambert J. MEDICAL AND SURGICAL MANAGEMENT OF PARANEOPLASTIC PYODERMA GANGRENOSUM - A CASE REPORT AND REVIEW OF THE LITERATURE. Acta Clinica Belgica 2014;65:37-40. [DOI: 10.1179/acb.2010.005] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
10 Calonje E, Brenn T, Lazar A. Neutrophilic and eosinophilic dermatoses. McKee's Pathology of the Skin. Elsevier; 2012. pp. 631-57. [DOI: 10.1016/b978-1-4160-5649-2.00015-9] [Cited by in Crossref: 5] [Article Influence: 0.6] [Reference Citation Analysis]